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ABSTRACT  26 
Study question: What is an objective approach that employs measurable and 27 
reproducible physiologic changes as the basis for classification of ovarian 28 
hyperstimulation syndrome (OHSS) in order to facilitate more accurate reporting of 29 
incidence rates within and across clinical trials?   30 
Summary answer: The OHSS flow diagram is an objective approach that will 31 
facilitate consistent capture, classification and reporting of OHSS within and across 32 
clinical trials.  33 
What is known already: OHSS is a potentially life-threatening iatrogenic 34 
complication of the early luteal phase and/or early pregnancy after ovulation 35 
induction or ovarian stimulation. The clinical picture of OHSS (the constellation of 36 
symptoms associated with each stage of the disease) is highly variable, hampering 37 
its appropriate classification in clinical trials. Although some degree of ovarian 38 
hyperstimulation is normal after stimulation, the point at which symptoms transition 39 
from anticipated to those of a disease state is nebulous.   40 
Study design, size, duration: An OHSS working group comprised of subject matter 41 
experts and clinical researchers who significantly contributed to the field of fertility 42 
was convened in April and November 2014.  43 
Participants/materials, setting, methods: The OHSS working group was tasked 44 
with reaching a consensus on the definition and classification of OHSS for reporting 45 
in clinical trials. The group engaged in targeted discussions regarding the scientific 46 
background of OHSS, the criteria proposed for the definition and the rationale for 47 
universal adoption. An agreement was reached after discussion with all members.   48 
Main results and the role of chance: One of the following conditions must be met 49 
prior to making the diagnosis of OHSS in the context of a clinical trial: 1) The subject 50 
has undergone ovarian stimulation (either controlled ovarian stimulation [COS] or 51 
ovulation induction [OI]) AND has received a trigger shot for final oocyte maturation 52 
(e.g., hCG  GnRH  agonist [GnRHa] or kisspeptin) followed by either fresh transfer or 53 
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segmentation (freeze all) or 2) The subject has undergone COS or OI AND has a 54 
positive pregnancy test. All study patients who develop symptoms of OHSS should 55 
undergo a thorough examination. An OHSS flow diagram was designed to be 56 
implemented for all subjects with pelvic or abdominal complaints, such as lower 57 
abdominal discomfort or distention, nausea, vomiting, and diarrhea, and/or for 58 
subjects suspected of having OHSS. The diagnosis of OHSS should be based on the 59 
flow diagram.  60 
Limitations, reasons for caution: This classification system is primarily intended to 61 
address the needs of the clinical investigator undertaking clinical trials in the field of 62 
controlled ovarian stimulation and may not be applicable for use in clinical practice or 63 
with OHSS occurring under natural circumstances. 64 
Wider implications of the findings: The proposed OHSS classification system will 65 
enable an accurate estimate of the incidence and severity of OHSS within and across 66 
clinical trials performed in women with infertility. 67 
Study Funding/competing interests: Financial support for the advisory group 68 
meetings was provided by Merck & Co. Inc., Kenilworth, NJ. P. Humaidan, S.M. 69 
Nelson, P. Devroey, C.C. Coddington, J.L. Frattarelli, H.M. Fatemi, and P. Lutjen 70 
report no relationships that present a potential conflict of interest. B.C. Tarlatzis 71 
reports grants and honorarium from Merck Serono; unrestricted research grants, 72 
travel grants and honorarium, and participation in a company-sponsored speaker’s 73 
bureau from Merck Sharp & Dohme; grants, travel grants, honoraria, and advisory 74 
board membership from IBSA; travel grants from Ferring; and advisory board 75 
membership from Ovascience.  L.B. Schwartz reports current employment with 76 
Merck & Co,, Inc., Kenilworth, NJ, USA, and owns stock in the company. K. Gordon 77 
and B.J. Stegmann report prior employment with Merck & Co., Inc., Kenilworth, NJ, 78 
USA, and own stock in the company. All reported competing interests are outside the 79 
submitted work. No other relationships or activities exist that could appear to have 80 
influenced the submitted work. 81 
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INTRODUCTION 89 
Ovarian hyperstimulation syndrome (OHSS) is a potentially lethal iatrogenic 90 
complication of the early luteal phase or/and early pregnancy after ovulation 91 
induction (OI) or controlled ovarian stimulation (COS). The incidence of clinically 92 
significant OHSS is 2 to 3%, and milder forms may develop in up to 20 to 30% of all 93 
in vitro fertilization (IVF) patients (Papanikolaou et al., 2006). In comparison to long 94 
gonadotropin-releasing hormone (GnRH) agonist (GnRHa) protocols, the risk of 95 
severe OHSS is reduced by approximately 50%, using GnRH antagonists for co-96 
treatment during COS prior to IVF or intra-cytoplasmic sperm injection (ICSI) 97 
treatment; importantly, both protocols provide equal efficacy in terms of reproductive 98 
outcome. Nevertheless, moderate or severe OHSS may still occur in GnRH 99 
antagonist protocols, primarily if human chorionic gonadotropin (hCG) is 100 
administered to trigger final oocyte maturation in high responder patients (Tarlatzis et 101 
al., 2012). 102 
A recent consensus conference was convened in Harbin, China with the goal of 103 
modifying the CONSORT checklist to improve the quality of reporting of clinical trials 104 
that test infertility treatments (Harbin Consensus Conference Workshop Group). The 105 
group identified OHSS resulting from OI or COS as a potential harm that merits 106 
reporting in clinical trials (Harbin).This is challenging since the clinical picture of 107 
OHSS (i.e., the constellation of symptoms associated with each stage of the disease) 108 
is highly variable, hampering the appropriate capture and uniform classification of 109 
OHSS in the clinical research setting. Whereas some degree of ovarian 110 
hyperstimulation is expected with the use of follicular stimulants, the point at which 111 
symptoms transition from anticipated effects to those indicative of a disease state is 112 
nebulous.  113 
The aim of this report is to describe an objective approach that employs 114 
measurable and reproducible physiologic changes as the basis for classification of 115 
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OHSS in order to facilitate more accurate reporting of incidence rates within and 116 
across clinical trials performed in women with infertility.  117 
 118 
OHSS 119 
Pathophysiology 120 
The primary physiologic change underlying OHSS is an increase in vascular 121 
permeability, resulting in fluid shift from the intravascular to third space 122 
compartments (Tollan et al., 1990; Goldsman et al., 1995; Geva and Jaffee, 2000). 123 
Pro-angiogenic vascular endothelial growth factor (VEGF) is an important mediator of 124 
OHSS (Pellicer et al., 1999; Garcia-Velasco and Pellicer, 2003), and serum VEGF 125 
levels have been shown to correlate with OHSS severity (Geva and Jaffee, 2000). In 126 
addition, hCG has been shown to increase VEGF expression in human granulosa 127 
cells, with related increases in VEGF concentration (Neulen et al., 1995; Pellicer et 128 
al., 1999). Other mediators that have been implicated in the pathogenesis of OHSS 129 
include angiotensin II, insulin-like growth factor 1, and interleukin-6 (The Practice 130 
Committee of ASRM, 2006). 131 
 132 
Risk Factors 133 
The factors associated with an increased risk of OHSS include young age (<30 134 
years) (Navot et al., 1988), low body weight, polycystic ovary syndrome (PCOS) or 135 
high basal antral follicle count (AFC) (Brinsden et al., 1995; Enskog et al., 1999; 136 
Humaidan et al.. 2010), elevated or rapidly increasing serum estradiol levels during 137 
COS (Delvigne and Rozenberg, 2002), history of an elevated response to 138 
gonadotropins (prior hyper-response or OHSS) (Navot et al., 1992), a large number 139 
of small follicles (8 to 12 mm) during ovarian stimulation (Navot et al., 1988), use of 140 
hCG instead of progesterone for luteal phase support after IVF (Navot et al., 1992), a 141 
large number of oocytes retrieved (>20) (Asch et al., 1991), early pregnancy (Enskog 142 
et al., 1999), and high basal anti-Müllerian hormone (AMH) concentrations 143 
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(Humaidan et al., 2010). Finally, ethnicity also seems to play a role, as African-144 
American women undergoing IVF have been reported to be at greater risk of 145 
developing OHSS than Hispanic or Caucasian women (Luke et al., 2009). 146 
 147 
Clinical Presentation 148 
The two types of OHSS are early onset, appearing <10 days after hCG 149 
administration, which is self-limited when no pregnancy occurs, and late onset, 150 
appearing ≥10 days after oocyte retrieval (Mathur et al., 2000). Early onset OHSS is 151 
associated with ovarian hyper-response to gonadotropin stimulation in patients 152 
predominantly triggered with hCG, whereas late onset OHSS is induced by hCG 153 
produced by the trophoblast of an implanting embryo. Cases comprised of early 154 
onset followed by late onset OHSS are often serious and prolonged (Papanikolaou et 155 
al., 2006).  156 
The clinical diagnosis of OHSS has been classified into different grades 157 
based on severity (Golan, 2009); however, it is of note that these grades are not 158 
strictly separated and can quickly transition. Most cases of OHSS are mild, self-159 
limited, and not of clinical concern. Symptoms of OHSS may begin as early as 24 160 
hours after the administration of hCG and increase in severity over the next 7 to 10 161 
days, usually related to the rise in endogenous hCG from early pregnancy (Delvigne 162 
and Rozenberg, 2003).  163 
The initial presentation of OHSS typically includes abdominal distension due 164 
to increased ovarian size; a progressive increase in abdominal circumference occurs 165 
as a result of accumulation of intraperitoneal fluid. Increased OHSS severity is the 166 
result of a further increase in vascular permeability and ascites leading to 167 
hemoconcentration. The associated reduction in intravascular volume may result in 168 
oliguria (Fabregues et al., 1998).  169 
As OHSS increases in severity, abdominal distension due to ascites may 170 
become more apparent, and enlarged ovaries filled with multiple corpus luteal cysts 171 
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may be detected via ultrasound. Electrolyte imbalance is often observed in severe 172 
OHSS (Rahami et al., 1997). In critical cases, women with pleural effusion may 173 
present with tachypnea or shortness of breath and untreated large pleural effusions 174 
have resulted in adult respiratory distress syndrome (Abramov et al., 1999). 175 
Thromboembolism is the most severe complication associated with OHSS (Hignett et 176 
al., 1995), and fatal cases have been reported (Cluroe and Synek, 1995). Thus, 177 
although OHSS reporting is a grey zone, a mortality rate of 3/100,000 after IVF/ICSI 178 
has been estimated in Europe (Braat et al., 2010). 179 
 180 
Prevention 181 
Although it is not possible to completely eliminate OHSS, significant reductions in 182 
incidence can be achieved with early identification of risk factors and careful clinical 183 
management of women undergoing COS. Prevention measures for OHSS are 184 
categorized into primary and secondary types. Primary prevention strategies focus 185 
on personalizing the stimulation protocol to an individual patient’s risk factors for 186 
ovarian response. Secondary prevention strategies are used to avoid OHSS in 187 
patients who have had an excessive response to COS. 188 
 For the primary prevention of OHSS, exposure to gonadotropins should be 189 
tailored according to AMH and AFC in first treatment cycles (Humaidan et al., 2010) 190 
or previous responses to COS with exogenous gonadotropins. Women with PCOS, 191 
history of OHSS, thrombophilia, family history of thromboembolism, and 192 
antiphospholipid antibodies should be identified prior to the initiation of COS, and 193 
treatment in these women should proceed at the lowest effective gonadotropin dose 194 
with routine monitoring (frequent vaginal ultrasonography and/or serum estradiol 195 
measurements). A variety of protocols have been used to accomplish this goal, 196 
including low-dose step-up, limited ovarian stimulation, and mild stimulation 197 
treatment and withholding FSH on the day of hCG trigger. An important primary 198 
OHSS prevention strategy is the use of GnRH antagonist protocols. Current scientific 199 
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evidence supports the hypothesis that GnRH antagonist co-treated cycles result in a 200 
significantly lower incidence of OHSS relative to GnRHa cycles. It is important that 201 
each woman undergoing treatment with gonadotropins be informed of her personal 202 
risk for OHSS, and encouraged to obtain a medical consult at the occurrence of 203 
symptoms.   204 
 The latest and probably most efficient secondary OHSS prevention strategy is 205 
GnRHa triggering of final oocyte maturation. The use of GnRHa for trigger secures 206 
sufficient oocyte maturation and significantly reduces, and in most cases, eliminates 207 
the risk of OHSS. However, GnRHa trigger can only be applied to cycles co-treated 208 
with a GnRH antagonist, which are the minority of cycles since the long GnRHa 209 
down-regulation protocol is still the most preferred protocol by clinicians worldwide 210 
(Tobler et al., 2014). Recently, kisspeptin was used to trigger final oocyte maturation 211 
in patients at risk of OHSS development; however, more data are needed to draw 212 
firm conclusions as to this novel trigger concept (Abbara et al., 2015). Another 213 
modification includes lowering the dose of hCG used for trigger, although this does 214 
not reduce the risk of late onset OHSS (Humaidan et al., 2010).  215 
Additional secondary prevention strategies include cycle cancellation 216 
(withholding hCG), segmentation (cryopreservation of embryos), and administration 217 
of macromolecules. In cycle cancellation, withholding hCG for ovulation induction 218 
prevents the early and late forms of OHSS. In GnRHa co-treated cycles, cancellation 219 
is a difficult decision; however, it may be the preferred method to avoid deleterious 220 
consequences in patients with an extreme ovarian response to stimulation. In 221 
segmentation, a bolus of GnRHa is administered, oocytes are retrieved and all 222 
embryos are frozen (Devroey et al., 2011; Maheswari and Bhattacharya, 2013). 223 
Although this approach does not completely eliminate the risk of early OHSS (Fatemi 224 
et al., 2014; Gurbuz et al., 2014; Ling LP et al., 2014), it does avoid the late form of 225 
OHSS associated with pregnancy. Finally, prophylactic administration of 226 
macromolecules, like hydroxyethyl starch solution (HEAS), has been suggested to 227 
 10 
reduce the risk of OHSS development by increasing the plasma osmotic pressure 228 
and binding mediators of ovarian origin (Graf, 1997; Knig et al., 1998; Gokmen et al., 229 
2001; Aboulghar et al., 2002; Bellver et al., 2003; Delvigne et al., 2003). However, 230 
recent studies show an increased risk of mortality in patients with sepsis (Westphal et 231 
al., 2009; Public Workshop 2015) and an increased risk of kidney injury requiring 232 
dialysis in critically ill patients (Westphal et al., 2009; Van Der Linden et al., 2013; 233 
Public Workshop 2015) following treatment with HEAS, warranting a careful risk-234 
benefit assessment prior to its use (Westphal et al., 2009; Van Der Linden et al., 235 
2013; Public Workshop 2015). The available macromolecule studies are limited by 236 
small sample sizes and disparate results, underlining the need for additional clinical 237 
research. 238 
 239 
Treatment 240 
The treatment approach for the clinical management of OHSS is multi-faceted and 241 
individualized based on disease severity and progression. Once the diagnosis of 242 
OHSS has been made, the disease severity should be determined. Outpatient 243 
management is recommended for women with milder forms of OHSS. The elements 244 
of outpatient follow-up include daily fluid balance, daily weighing, assessment of 245 
increase in umbilical abdominal circumference, blood tests and ultrasound 246 
examination every 48 to 72 hours and instruction to contact the clinic at any sign of 247 
deterioration. Outpatient culdocentesis/paracentesis should be considered to prevent 248 
OHSS disease progression on a case-by-case basis. 249 
 The criteria for hospitalization due to OHSS are hematocrit >45% and/or any 250 
sign of pulmonary or hemodynamic compromise. Inpatient treatment of OHSS 251 
includes maintenance of diuresis with fluid management and administration of 252 
albumin if indicated due to hypo-albuminemia (<28 mg/dL); administration of anti-253 
coagulant drugs in patients with a documented history of thrombophilia, history of 254 
hypercoagulability or thrombo-embolism, and uncorrected hemoconcentration after 255 
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48 hours of usual intravenous treatment; and culdocentesis/paracentesis. 256 
Hospitalized patients must be visited frequently, as the clinical picture may change 257 
rapidly. When critical OHSS develops, the patient must be admitted to the intensive 258 
care ward. Only in very critical cases should interruption of an early pregnancy be 259 
considered. Treatment with cabergoline (0.5 mg daily for 8 days) (Alvarez et al., 260 
2007; Gaafar et al., 2014) and cabergoline with a GnRH antagonist (0.5 mg orally for 261 
7 days plus 250 mcg ganirelix SC daily for 2 days) (Rollene et al., 2009) have been 262 
recommended to reduce the VEGF and subsequently the effects of OHSS; . 263 
 264 
REVIEW OF EXISTING PUBLISHED CLASSIFICATION 265 
A detailed classification for OHSS was first proposed by Rabau et al. in 1967, which 266 
was later reorganized by Schenker and Weinstein in 1978, based on clinical 267 
presentation and laboratory findings. This early classification system divided the 268 
syndrome into three categories (mild, moderate and severe) and six grades of 269 
severity. In 1989, a revised OHSS classification system was proposed by Golan et 270 
al., which included four major modifications to the earlier system: 1.) urinary assays 271 
of hormones were omitted; 2.) the diagnosis of ovarian enlargement and the 272 
detection of ascites were ultrasound based; 3.) nausea, vomiting and diarrhea and 273 
abdominal distension were moved from moderate to mild (grade 2) OHSS; and 4.) 274 
the detection of ascites by transvaginal ultrasonography established the diagnosis of 275 
moderate OHSS (grade 3).  276 
Additional refinements were since published. In 1992, Navot et al. defined a 277 
‘critical’ category of OHSS and, in 1999, Rizk and Aboulghar subcategorized severe 278 
OHSS into three Grades (A, B and C), with ‘Grade C’ being the most severe form. 279 
Both updates describe life-threatening OHSS, including complications such as renal 280 
failure, thromboembolism and adult respiratory distress syndrome. These symptoms 281 
are considered as ‘Grade 6 OHSS’ in the modern classification by Golan (Golan, 282 
2009). In 2010, Humaidan and colleagues provided a classification scheme for 283 
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grading OHSS that incorporates vaginal sonography and laboratory parameters to 284 
objectively relate symptoms to severity (Humaidan et al., 2010). In this system, mild, 285 
moderate and severe forms of OHSS are distinguished by the extent of fluid shift into 286 
body cavities, with moderate disease defined by shifts of less than 500 mL, and 287 
severe disease characterized by laboratory signs of hepatorenal dysfunction due to 288 
hemoconcentration and hypovolemia (Humaidan et al., 2010). The authors offered 289 
practical, evidence-based guidance to reduce the occurrence of OHSS, and cited 290 
GnRH antagonist protocols and GnRHa trigger as the most important risk reduction 291 
strategies, very effective when used in combination (Humaidan et al., 2010). 292 
Recently, the Royal College of Obstetricians & Gynaecologists published updated 293 
evidence-based guidelines to help clinicians diagnose and manage patients with 294 
OHSS (Green-top Guideline 2016).   295 
 296 
METHODS 297 
An OHSS working group comprised of subject matter experts and clinical 298 
researchers who significantly contributed to the field of fertility was convened in April 299 
and November 2014 (Appendix I). The scientific advisory group was tasked with 300 
reaching a consensus on the definition and classification of OHSS for reporting in 301 
clinical trials. The group engaged in targeted discussions regarding the scientific 302 
background of OHSS, the criteria proposed for the definition and the rationale for 303 
universal adoption. An agreement was reached after discussion with all members.   304 
 305 
CLASSIFICATION OF OHSS IN THE CLINICAL TRIAL SETTING 306 
Current classification systems are inadequate to uniformly capture OHSS in the 307 
clinical research environment, as they are often subjective and do not account for the 308 
wide variations in the presentation of OHSS. Thus, the following OHSS flow diagram 309 
is proposed to facilitate consistent capture, classification and reporting of OHSS in 310 
the clinical trial setting (Figure 1). 311 
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In a clinical trial, one of the following conditions must be met prior to making 312 
the diagnosis of OHSS: 1) The subject has undergone ovarian stimulation (either 313 
COS or ovulation induction [OI]) AND has received hCG, GnRHa or kisspeptin 314 
trigger; or 2) The subject has undergone COS or OI AND has a positive pregnancy 315 
test.  316 
Following ovarian stimulation, response may be either exaggerated or normal 317 
(Zegers-Hochschild et al., 2009; Personal communication S. Vanderpoel [WHO] to B. 318 
Stegmann, 2015). Women with exaggerated responses to stimulation are at 319 
increased risk of OHSS, and although this risk may be mitigated with the use of 320 
GnRHa trigger, this group still represents a potential excessive response to treatment 321 
which warrants reporting in the clinical trial setting. Women with a normal response to 322 
stimulation receive hCG trigger, and are screened for symptoms and signs of OHSS 323 
on the day of embryo transfer, the day of positive pregnancy test, and/or at the time 324 
of complaint.  325 
Screening may reveal classic symptoms of OHSS (nausea, vomiting, 326 
abdominal discomfort and/or bloating) and/or clinical signs of OHSS (weight gain, 327 
tachycardia/orthostatic changes, tachypnea with dyspnea). The presence of these 328 
symptoms and/or signs alone is not sufficient to make a diagnosis of OHSS, and 329 
additional screening tests (ultrasound for ascites, liver function tests, electrolytes, 330 
hematocrit, serum Cr, 24-hour urine output) are necessary.  331 
A woman without positive findings on additional screening is considered an 332 
ovarian hyper-responder, not a diagnosed case of OHSS. For these women, 333 
continued surveillance is warranted, and reporting in the clinical trial is encouraged. 334 
By contrast, even one positive finding at additional screening along with classic 335 
symptoms and/or clinical signs of OHSS is sufficient to make the diagnosis of OHSS. 336 
Women in this group require close monitoring, and reporting in the clinical trial is 337 
required.  338 
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Once it is determined that OHSS is present, it is further classified into self-339 
limited OHSS or OHSS with significant co-morbidities. In self-limited OHSS, the 340 
disease eventually resolves completely, without the development of significant or 341 
permanent comorbidities. Some treatments such as culdocentesis or prophylactic 342 
anticoagulation may be required, but the disease does not progress to a catastrophic 343 
event. When a catastrophic event does occur, the sub-category of OHSS with 344 
significant co-morbidity is applied. The occurrence of any of the following five 345 
catastrophic events qualify for this sub-category classification: 1.) Venous 346 
thromboembolism; 2.) Acute Respiratory Distress Syndrome; 3.) Cerebral 347 
edema/acute ischemia/encephalopathy; 4.) Acute kidney injury (per the AKIN and 348 
KDIGO guidelines); and/or 5.) Liver failure (elevated liver enzymes with hepatic 349 
encephalopathy and an elevated PT/INR). For the purposes of reporting OHSS in a 350 
clinical trial, only the highest level of disease is reported, and women cannot have 351 
more than one classification for OHSS. 352 
 353 
CONCLUSIONS AND FUTURE RECOMMENDATIONS 354 
The universal adoption of consistently applied criteria by which to define OHSS 355 
utilizing the OHSS flow diagram for future clinical trials has the goal of producing 356 
homogeneous results, reducing bias caused by spurious definitions and enabling 357 
valid comparisons within and across clinical trials on which to base reliable 358 
conclusions. The uniformity of the resulting data would be expected to increase 359 
transparency of the risk-benefit ratio of infertility treatments and ultimately improve 360 
medical care. This standard approach should also enable an accurate means by 361 
which to estimate the true incidence and severity of OHSS.  Future studies should be 362 
designed to implement the OHSS flow diagram and measure outcome.  Importantly, 363 
this process of diagnosing OHSS is primarily intended to address the needs of the 364 
clinical investigator undertaking clinical trials in the field of COS.  365 
 366 
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FIGURE LEGEND 
Figure 1. Ovarian hyperstimulation syndrome flow diagram for use in the clinical trial 
setting. †Exaggerated response, as defined by World Health Organization criteria. 
‡Subjects to be screened for ovarian hyperstimulation syndrome symptoms on the 
day of embryo transfer, the day of positive pregnancy test, or at time of complaint. 
Shaded shapes denote required reporting of group in the context of a clinical trial.  
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References for quantitative abnormalities in Figure 1 
Examination 
Findings 
Significant Alterations Normal Reference 
Weight gain ≥2 lbs (0.91 kg)/day for 
2 days or a total 
increase of 5 lbs (2.27 
kg) from the beginning 
of the stimulation period 
-- Practice Bulletin 
ASRM 
Tachycardia over 100 beats/min varies by patient American Heart 
Association 
Tachypnea over 20 breaths/min at 
rest 
12-20 at rest Mosby's Medical 
Dictionary, 8th 
edition 
Oliguria <0.5 mL/kg/hr for >6 hr 
or a 24 hr negative fluid 
balance of 500 mL 
varies Acute Kidney Injury 
Network (AKIN) 
Guidelines 
Ascites 
   Grade 1 
    
   Grade 2  
 
 
   Grade 3 
 
visible only on US or 
CT* 
detectable with flank 
bulging or shifting 
dullness 
marked distension 
no fluid present Moore et al, 
Hepatology 20031 
 
Parameter Significant Alterations Normal Range Reference 
Liver Function Test 
    AST 
     
    ALT 
    
 Total Bilirubin 
 
    GGT 
 
2X upper limits of  
normal range 
2X upper limits of  
normal range 
any elevation above 1.0 
2X normal 
 
<31 U/L 
 
<31 U/L 
 
0.2-1.0 mg/dL 
 
0-52 U/l 
 
 
 
 
Chen et al. HR 20002 
Electrolytes 
    Sodium 
    Potassium 
 
less than 132 mEq/L 
more than 5.0 mEq/L 
 
135-145 mEq/L 
3.5-5.0 mEq/L 
 
 
Practice Bulletin 
ASRM 
Hematologic  
    Hematocrit 
 
     
   
over 45% or evidence 
of a >10% increase in 
HCT 
 
 
36-46% 
 
 
 
 
Practice Bulletin 
ASRM 
Renal Function 
  Serum Cr (SCr) 
 
Increase in SCr ≥ 0.3 
mg/dL or increase to  
≥ 150% above initial 
baseline levels  
 
0.6-1.1 mg/dL 
 
Acute Kidney Injury 
Network (AKIN) and 
Kidney Disease 
Improving Global 
Outcomes (KDIGO) 
Clinical Practice 
Guidelines  
*Either abdominal or transvaginal scan. 
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